TY - JOUR
T1 - Aurora kinase A inhibition
T2 - A mega-hit for myelofibrosis therapy?
AU - Piszczatowski, Richard T.
AU - Steidl, Ulrich
N1 - Funding Information:
R.T. Piszczatowski is supported by the NCI of the NIH under Award Number F30CA217063. U. Steidl is the Diane and Arthur B. Belfer Scholar in Cancer Research of the Albert Einstein College of Medicine, and is a Research Scholar of the Leukemia and Lymphoma Society.
Publisher Copyright:
Ó2019 American Association for Cancer Research.
PY - 2019
Y1 - 2019
N2 - The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.
AB - The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.
UR - http://www.scopus.com/inward/record.url?scp=85070723611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070723611&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-1481
DO - 10.1158/1078-0432.CCR-19-1481
M3 - Article
C2 - 31196854
AN - SCOPUS:85070723611
SN - 1078-0432
VL - 25
SP - 4868
EP - 4870
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -
